Formycon AG Confirms 2025 Guidance Amid Pipeline and Partnership Progress

Formycon AG has reported its financial results for the first nine months of 2025. The company maintained its guidance for the year, emphasizing pipeline progress and strategic partnerships as key drivers for future growth.

Revenue totaled €19.5 million, down from €41.1 million the previous year, largely due to a shift towards recurring revenue sources instead of one-time payments. The Stelara® biosimilar FYB202 saw increased market penetration, with significant progress in both the US and European markets.

Operational and strategic developments have paved the way for sustainable growth. With the successful completion of patient recruitment for the FYB206 study and new regulatory guidelines in the US, Formycon is poised to accelerate biosimilar approvals.

Formycon's financial strategy is anchored by its first corporate bond issuance, providing a solid framework for ongoing development and commercialization efforts. As the company consolidates its resources, it aims for EBITDA-positive results by 2027.